Kornimate/medical-research-clean huggingface dataset:
the use of 18f-alf-nota-prgd2 pet/ct scan to predict the efficacy and adverse events of apatinib in malignancies.

Conditions: Malignancies; Stomach Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Breast Cancer; Ovary Cancer; Cervical Cancer

Summary: this is an open-label, single arm study to explore whether 18f-alf-nota-prgd2 pet/ct scan can predict the efficacy and adverse events of apatinib in patients with malignancies. integrin αvβ3 has been shown to play an important role in angiogenesis and up-regulated obviously in various types of tumor cells and activated endothelial cells. the arginine-glycine-aspartic acid (rgd) tripeptide sequence can bind to integrin αvβ3 with high affinity and specificity. the 18f-alf-nota-prgd2 will highly combine with αvβ3, and thus will monitor the antiangiogenic status.in the current study, investigators propose to evaluate the feasibility of 18f-rgd pet/ct in monitoring efficacy and adverse events of apatinib in malignancies.

this is an open-label, single arm study to explore whether 18f-alf-nota-prgd2 positron emission tomography/computed tomography (18f-rgd pet/ct) scan can predict the efficacy and adverse events of apatinib in patients with malignancies. angiogenesis, the formation of new blood vessels, is the process of generating neovascularization from preexisting vessels. it can promote tumor growth and metastasis by providing nutrients and oxygen. integrin αvβ3 has been shown to play an important role in angiogenesis and up-regulated obviously in various types of tumor cells and activated endothelial cells. since the arginine-glycine-aspartic acid (rgd) tripeptide sequence can bind to integrin αvβ3 with high affinity and specificity, rgd pet/ct may be helpful to evaluate the biological and metabolic activity status during angiogenesis. however, 18f-alf-nota-prgd2 pet/ct as response biomarker for antiangiogenic therapy has not been fully proved and is still without universal understanding according to current publications. apatinib (yn968d1) is the first orally antiangiogenic drug targeting vegfr-2 tyrosine kinase.in the current study, investigators propose to evaluate the feasibility of 18f-rgd pet/ct in monitoring efficacy and adverse events of apatinib in malignancies. patients confirmed malignancies histopathologically will be prospectively enrolled in the study. all patients provided written informed consent prior to enrollment. patients will receive apatinib therapy, and undergo 18f-rgd pet/ct scans berore and after first cycle of therapy.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of malignancies * scheduled for second- or third-line apatinib therapy * karnofsky performance status (kps) ≥70 * measurable primary tumors according to response evaluation criteria in solid tumors (recist) exclusion criteria: * active infection, myocardial infarction within 6 months, symptoms of heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy * the claustrophobic patients and patients with implanted metal objects * the pregnancy * inability to complete the required examinations

Keywords: rgd pet-ct apatinib
performance evaluation of an advanced algorithm with cgm in adults, adolescents, and pediatrics

Conditions: Type 1 Diabetes Mellitus; Type2 Diabetes Mellitus

Summary: the purpose of this study is to demonstrate the performance of the guardian™ sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).

the study is a multi-center, prospective, single-sample correlational design without controls. the purpose of this study is to demonstrate the performance of the guardian™ sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).

Eligibility criteria:
inclusion criteria: 1. individual is 2 - 80 years of age at time of enrollment 2. a clinical diagnosis of type 1 or 2 diabetes for a minimum of 6 months duration as determined via medical record or source documentation by an individual qualified to make a medical diagnosis 3. adequate venous access as assessed by investigator or appropriate staff 4. subjects participating in the high and low glucose challenges must have an insulin carbohydrate ratio(s) and insulin sensitivity ratio. subjects without ratios may participate under observation only exclusion criteria: 1. subject will not tolerate tape adhesive in the area of guardian™ sensor (3) placement as assessed by a qualified individual. 2. subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, staphylococcus infection) 3. subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks 4. subject is female and has a positive pregnancy screening test 5. female of child bearing age and who is sexually active should be excluded if she is not using a form of contraception deemed reliable by investigator 6. subject is female and plans to become pregnant during the course of the study 7. subject has had a hypoglycemic seizure within the past 6 months prior to enrollment 8. subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to enrollment. 9. subject has had an episode of diabetic ketoacidosis (dka) within the past 6 months prior to enrollment. 10. subject has a history of a seizure disorder 11. subject has central nervous system or cardiac disorder resulting in syncope 12. subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (tia), cerebrovascular accident (cva), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease 13. subject has a hematocrit (hct) lower than the normal reference range (please note that patients may use prior blood draw from routine care as long as done within 6 months of screening and report of lab placed with subject source documents) 14. subject has a history of adrenal insufficiency 15. subject is a member of the research staff involved with the study.
effect of lollipop on postoperative gastrointestinal recovery in children

Conditions: Ileus Postoperative

Summary: postoperative ileus is common in children. there are various method to prevent postoperative ileus. in this study, the investigators will explore the role of sucking lollipop after operation on the recovery of gastrointestinal function in children.

postoperative ileus is a common occurrence among children undergoing major operations, including gastrointestinal and spinal surgeries. it can result in physical discomfort, extended hospital stays, delayed resumption of activity and poor satisfaction with surgical care. the pathophysiology and course of postoperative ileus occurs in three phases: increased sympathetic activity, release of inflammatory mediators and vagal activation as ileus resolves. multiple risk factors of postoperative ileus have been identified in various studies, including general risk factors such as significant blood loss, male gender and medical comorbidities like chronic obstructive pulmonary disease (copd), as well as risk factors specific to the surgery, such as the laparotomy approach, emergency surgery and stoma formation. chewing gum, as a form of sham feeding, has been employed in adults and children as a modality to decrease risk of postoperative ileus. there has been concrete evidence that it could result in expedited recovery of gastrointestinal function after surgery in adult populations. however, it may not be a feasible option for infants and young children. lollipop, on the other hand, is easier to apply in children which only require the action of sucking. it can stimulate the cephalic phase of digestion via vagal cholinergic stimulation and release of gastrointestinal hormone (gastrin and motilin) through its taste and absorption of sugar. the current evidence of lollipop in the recovery of postoperative gastrointestinal function in children is limited with only two randomised controlled trial published so far with satisfactory outcomes, yet both were not indexed and were not carried out in accordance with consolidated standards of reporting trials (consort). based on these reasons, the investigators plan to carry out a prospective, multiple-centred, non-blinded, randomized controlled trial using a parallel arm design on the effect of lollipop on recovery of gastrointestinal function after operation in children. children recruited will be randomly assigned into either lollipop group or non-treatment group; lollipop will be given to children in treatment group after operation. their outcomes will be compared.

Eligibility criteria:
inclusion criteria: * patients receiving major abdominal surgery (e.g.appendicectomy, choledochal cyst surgery, bowel resection etc) exclusion criteria: * patients with neurological conditions that preclude sucking/swallowing. * patients under sedation and/or mechanical ventilation and/or ionotropic support in the post operative period. * patients with known food allergy or allergy to food coloring agents
on the safety, tolerability, and efficacy of utaa09 injection in the treatment of lymphoma

Conditions: Recurrent or Refractory B-cell Non Hodgkin's Lymphoma

Summary: the main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of utaa09 cell preparation in the treatment of relapsed/refractory b-cell non hodgkin's lymphoma patients. the secondary research objective is to explore the clinical efficacy of utaa09 injection after administration and to explore the content of cd19 positive b cells in peripheral blood after utaa09 injection administration.

single dose, single arm trial, exploring the initial 28 day safety and efficacy of the investigational drug.

Eligibility criteria:
inclusion criteria: 1. subjects voluntarily participate in clinical studies; 2. ecog score 0-1 points; 3. histologically confirmed large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and inert lymphoma transformed into diffuse large b-cell lymphoma; cd19 and/or cd20 positivity; 4. at least one measurable tumor lesion determined according to lugano's criteria: the longest diameter of intranodal lesions\>1.5cm, and the longest diameter of extranodal lesions\>1.0cm. exclusion criteria: 1. received other chimeric antigen receptor therapy or gene modified cell therapy before screening; 2. subjects who were undergoing systemic steroid therapy during screening and were determined by the researchers to require long-term use of systemic steroid therapy during the treatment period (excluding inhalation or local use); 3. any unstable heart disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (new york heart association \[nyha\] classification ≥ iii), and severe arrhythmia.
prehabilitation care for women with advanced ovarian cancer receiving neoadjuvant chemotherapy

Conditions: Ovarian Cancer; Stage III Ovarian Cancer; Stage IV Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma; Fallopian Tube Cancer

Summary: the purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.


Eligibility criteria:
inclusion criteria: * subjects must be diagnosed with stage iii or stage iv ovarian carcinoma (which includes primary peritoneal carcinoma or fallopian rube carcinoma) * all subjects must be enrolled within 90 days of diagnosis * no prior treatment for ovarian carcinoma * all subjects have agreed to a treatment plan of neoadjuvant chemotherapy and subsequent planned interval debulking surgery with an mskcc surgeon * participants must be initiating treatment at gynecologic medical oncology clinics at mskcc manhattan * proficiency in english in the determination of the investigators of by patient self-report exclusion criteria: * patient under age 18 * prior treatment for ovarian cancer * second opinion visit only * immediate surgery plan without neoadjuvant treatment * no intended surgical plan * chemotherapy administration exclusively planned at mskcc regional site * patient unwilling to sign consent

Keywords: ovarian cancer primary peritoneal carcinoma fallopian tube cancer 19-347 memorial sloan kettering cancer center
single perclose escalation technique for vascular closure in tavr

Conditions: Aortic Valve Stenosis; Structural Valve Deterioration; Structural Valve Degeneration

Summary: this study examines in the safety and efficacy of using a single perclose escalation technique (spet) using a single perclose proglide device to preclose and the need for a rescue device based on a control angiography at the end of the procedure, with a 6f femoral sheath.

percutaneous femoral access is the preferred access route for transcatheter aortic valve replacement (tavr). the majority of experienced tavr centers use two 6f perclose proglide™ devices to close the primary vascular access site, deployed prior to upsizing sheath size with closure completed at the end of the case (the double "preclose" approach). a strategy of utilizing a single perclose device to preclose may have advantages including fewer complications, complexity, and cost, but the safety of this is unknown. this study examines in the safety and efficacy of using a single perclose escalation technique (spet) using a single perclose proglide device to preclose and the need for a rescue device based on a control angiography at the end of the procedure, with a 6f femoral sheath. the use of femoseal in mild bleedings, and a second perclose proglide for moderate to severe bleedings. compare this spet technique with double preclose technique, with two historical cohorts of patients. one cohort of patients with spet technique since started this technique, and a second cohort with double perclose technique prior to starting spet technique.

Eligibility criteria:
inclusion criteria: * patients older than 18 years * patients who have undergone transfemoral tavi implantation exclusion criteria: * patients who do not meet the inclusion criteria

Keywords: residual stenosis
study of extensive clinical target volumes in postoperative radiotherapy concurrent with chemotherapy for esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma

Summary: the purpose of this study is to evaluate safety and 2-year local control rate for extensive clinical target volumes in postoperative radiotherapy concurrent with chemotherapy for esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: * joined the study voluntarily and signed informed consent form; * age 18-75; * ecog 0-2; * esophageal squamous cell carcinoma, radical surgery ≤ 3 months, r0 resection; * the operative incision healed well; * t3-4n0m0, t1-4n1-3m0 (according to ajcc2009); * no radiotherapy, chemotherapy or other treatments pre (post) surgery; * ps ecog 0-2; * life expectancy of more than 3 months; * hemoglobin (hb) ≥ 9 g/dl • wbc ≥ 3 x 109/l, neutrophils (anc ) ≥ 1.5 x 109/l • platelet count (pt) ≥ 100 x 109/l • hepatic function: alat and asat \< 2.5 x uln, tbil\< 1.5 x uln • renal function: creatinine \< 1.5 x uln * no immuno-deficiency; * use of an effective contraceptive for adults to prevent pregnancy. exclusion criteria: * complete esophageal obstruction after surgery, esophageal perforation, haematemesis; * other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years; * participation in other interventional clinical trials within 30 days; * pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives; * drug addiction, alcoholism or aids; * uncontrolled seizures or psychiatric diseases, loss of control over their own behavior; * unsuitable to be enrolled in the trial in the opinion of the investigators.
to compare therapeutic effect of intravitreal bevacizumab and triamcinolone in resistant uveitic cystoid macular edema

Conditions: Resistant Cystoid Macular Edema

Summary: cystoid macular edema (cme) is one of the common causes of vision loss in patients with uveitis .triamcinolone has been effectively used in reducing cme and improving the vision. also there are some documents which recommend bevacizumab(avastin) could reduce macular edema. this study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

this study compare intravitreous injection of triamcinolone and avastin in patients with resistant uveitic cystoid macular edema.

Eligibility criteria:
inclusion criteria: * uveitic cme * uveitic cme refractory to routine treatment * vision better than 5/200 and worse than 20/50 exclusion criteria: * mono- ocular patients * history of vitrectomy * glaucoma or ocular hypertension * history of other retinal disease that can cause macular edema * pregnancy * significant media opacity * vision better than 20/50

Keywords: resistant uveitic cystoid macular edema intravitreal triamcinolone intravitreal bevacizumab
study of mk-217a/alendronate sodium 70-mg/vitamin d3 5600 iu combination tablet (mk-0217a-329)

Conditions: Osteoporosis

Summary: this study will assess the effect of 26 weeks of once-weekly treatment with mk-217a/alendronate sodium 70-mg/vitamin d3 5600 iu combination tablet (fosamax plus 70/5600) on serum levels of 25-hydroxyvitamin d \[25(oh)d\].


Eligibility criteria:
inclusion criteria: * man aged 50 or older, or a woman who is postmenopausal on day of signing informed consent or has been menopausal for at least one year * meets bone mineral density (bmd) criteria * agree to discontinue any osteoporosis drug treatment for duration of study exclusion criteria: * any contraindication to alendronate and vitamin d * not ambulatory * has received treatment with any anabolic steroid agent within the past 12 months, systemic glucocorticoids, for more than 2 weeks in the past 6 months, current use of immunosuppressants, fluoride treatment at a dose greater than 1 mg/day for more than 2 weeks within the past 3 months, treated with parathyroid hormone (pth) for more than 2 weeks within the past 3 months, current use of chemotherapy or heparin, use of growth hormone for more than 2 weeks within the past 6 months, use of active hormonal vitamin d analogs in the past 2 months, current use of vitamin a \>10,000 iu daily, current use of, lithium, or anti-convulsants including barbiturates, hydantoins, and carbamazepine, current use of calcium supplement in amount excess of 1500 mg daily, and/or current use of vitamin d supplement * history of malignancy \<5 years, except adequately treated basal cell or squamous cell skin cancer and in situ cervical cancer * one or more of the following concomitant conditions: upper gastrointestinal (gi) disorders not adequately controlled; myocardial infarction, unstable angina, stroke and revascularization condition within 3 months; malabsorption syndrome; primary or secondary hyperparathyroidism not adequately treated; thyroid disease not adequately controlled; severe renal insufficiency; uncontrolled genitourinary, cardiovascular, hepatic, renal, endocrine, hematologic, neurological, psychiatric, or pulmonary diseases; uncontrolled hypertension; new onset diabetes (within 3 months), poorly controlled hyperglycemia, or hypoglycemia for any cause; evidence for metabolic bone disease other than osteoporosis; abnormal indices of calcium metabolism; and/or active renal stone disease * user of illicit recreational drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence * heavy consumer of alcohol or alcohol containing products.

Keywords: osteoporosis postmenopausal
comparison of i-124 pet/ct, f-18 fdg pet/ct & i-123 whole body scintigraphy for recurrent thyroid ca

Conditions: Thyroid Cancer

Summary: the management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (tg) involves imaging with iodine-123 whole body scintigraphy (i-123 wbs) and f-18 fdg pet/ct. however, the disease is not always detected. the use of another iodine isotope (i-124) with positron emitting characteristics for pet/ct may allow better identification of recurrent disease, thus allowing for more patients to be treated with i-131 as a curative attempt.

the management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (tg) involves imaging with iodine-123 whole body scintigraphy (i-123 wbs) and f-18 fdg pet/ct. however, the disease is not always detected. the use of another iodine isotope (i-124) with positron emitting characteristics for pet/ct may allow better identification of recurrent disease, thus allowing for more patients to be treated with i-131 as a curative attempt. conducting this study we hope to find whether i-124 pet/ct allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by i-123 wbs and f-18 fdg pet/ct.

Eligibility criteria:
inclusion criteria:- patient at nuclear medicine clinic at stanford university medical center * treated thyroid cancer. * detectable levels of tg. * referred for i-123 wbs and f-18 fdg pet/ct for detection of recurrent thyroid cancer. * able to have a i-124 pet/ct the day after i-123 wbs and f-18 fdg pet/ct * patients older than 18-year-old. * patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of tg. * patients must have i-123 wbs and f-18 fdg pet/ct performed prior to the i-124 pet/ct. * patients must understand and voluntarily sign an informed consent form after the contents have been fully explained to them. exclusion criteria:- patients who are not eligible for i-123 wbs and f-18 fdg pet/ct. * patients who cannot complete i-123 wbs and f-18 fdg pet/ct. * pregnant women. * healthy volunteers. * patients participating in other research studies.
implementation of guidelines for the management of arterial hypertension. the impulsion study

Conditions: High Blood Pressure

Summary: the objective of this protocol is to improve awareness, treatment, and control of arterial hypertension, within primary prevention of target organ damage, by implementing guidelines, after training of the participating physicians.

physicians from 20 hospitals and 40 health centres (primary health care settings) were trained to implement guidelines in treating arterial hypertension. there will be a baseline recording of patients with arterial hypertension and then physicians will have to complete a one page form (by ticking pre-specified boxes) about the baseline status of the patients and will have to report the measures they took to improve awareness, treatment, and effective control of arterial hypertension. after a six month effort, physicians will have to complete the same form at study completion. previous training of physicians and the fact that they will have to report their success in treating hypertension will hopefully contribute to an increase in number of hypertensive patients at blood pressure target, and will minimise the target organ damage. the estimated reduction in coronary heart disease risk will be evaluated by a comparison of this risk (as evaluated by a risk engine, i.e. procam) at study completion with that of baseline.

Eligibility criteria:
inclusion criteria: * arterial hypertension as defined by the jnc 7 report exclusion criteria: * pregnancy * lactation * malignancies with small life expectancy * unwillingness to participate

Keywords: high blood pressure awareness treatment effective control coronary heart disease risk reduction hypertension